文献速递瓣膜病与结构性心脏病

左心室导丝起搏在经导管主动脉瓣置换术中的应用

[Left ventricular guidewire pacing during transcatheter aortic valve replacement].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2021-01-01

本研究为回顾性研究,纳入2019年10至12月在阜外医院应用左心室导丝起搏行TAVR的13例患者。结果显示所有患者均完成球囊扩张和瓣膜释放,术中血压可降至60 mmHg以下,瓣膜位置稳定,住院及出院3个月随访期间无死亡、心肌梗死、卒中等主要心脏不良事件。结论认为左心室导丝起搏是TAVR中安全、可行的策略。

要点

  • 左心室导丝起搏下所有13例患者均成功完成TAVR。
  • 以180次/min起搏后血压均降至60 mmHg以下,瓣膜释放顺利。
  • 术后3例出现三度房室传导阻滞需临时起搏,其中1例住院期间植入永久起搏器。

核心结论

  • TAVR中使用左心室导丝起搏是安全、可行的。

研究设计与样本

  • 本研究为回顾性研究,纳入2019年10至12月于中国医学科学院阜外医院应用左心室导丝起搏技术行TAVR治疗的患者13例。

主要发现

  • 13例患者中男性7例,年龄为(73.8±8.3)岁;三叶式主动脉瓣9例,二叶式主动脉瓣3例,主动脉瓣人工生物瓣置换术后1例。
  • 球囊扩张时以180次/min起搏后血压均降至60 mmHg(1 mmHg=0.133 kPa)以下,瓣膜释放过程顺利且位置稳定。
  • 升主动脉造影显示瓣膜释放后无反流7例,轻度反流5例,中度反流1例。
  • 术中有3例因三度房室传导阻滞置入临时起搏导线,其中1例住院期间植入永久起搏器,另2例术后24 h内传导恢复;另有1例术后10 d出现三度房室传导阻滞并植入永久起搏器。
  • 住院及出院3个月随访期间无死亡、心肌梗死、卒中等主要心脏不良事件发生。

临床怎么用

  • 对于TAVR术中需要快速起搏降低血压的患者,可考虑采用左心室导丝起搏策略。
  • 术后需关注传导阻滞发生,必要时临时或永久起搏器植入。

局限性

  • 本研究为单中心回顾性研究,样本量较小(13例),随访时间较短(3个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the safety and efficacy of left ventricular guidewire pacing during transcatheter aortic valve replacement (TAVR). Methods: This is a retrospective study. Thirteen patients, who underwent TAVR with left ventricular guidewire pacing from October 2019 to December 2019 in Fuwai Hospital, were included. Clinical data and operational procedure data of the patients were collected. Changes in blood pressure and electrocardiogram were observed during operations. Ascending aorta angiography was performed to evaluate the regurgitation of aortic valve after valve implantion. The incidence of major adverse cardiac events during hospitalization and at 3-months after discharge was recorded. Results: There were 7 male and 6 female patients in this cohort,and age was (73.8±8.3) years old. Among the 13 patients, 9 were tricuspid aortic valves, 3 were bicuspid aortic valves, and 1 was degenerated bioprosthetic surgical aortic valve. TAVR were successfully performed in all of the 13 cases using pacing through the left ventricular guidewire. During balloon dilation, the blood pressure decreased to below 60 mmHg (1 mmHg=0.133 kPa) after 180 beats/min pacing, and the valve release process was smooth and the position was stable. The results of aortography showed that there was no regurgitation in 7 cases, mild regurgitation in 5 cases and moderate regurgitation in 1 case. Three patients required temporary pacing during the procedure due to complete heart block, among whom 1 patient was implanted with permanent pacemaker during hospitalization, and the other 2 patients recovered within 24 hours after operation. In another case, there was no significant change of electrocardiogram during the operation, and complete heart block occurred 10 days after the operation, and treated with permanent pacemaker. The other 10 patients began to carry out bedside activities and rehabilitation training 24 hours after operation. There was no death, myocardial infarction, stroke and other major adverse cardiac events during hospitalization and at 3-month follow-up after discharge. Conclusion: Left ventricular guidewire pacing is a safe and effective strategy for TAVR. 目的: 总结经导管主动脉瓣置换术(TAVR)中应用左心室导丝起搏技术的初步经验。 方法: 本研究为回顾性研究。收集2019年10至12月于中国医学科学院阜外医院应用左心室导丝起搏技术行TAVR治疗的患者13例。收集患者的临床资料、手术操作,术中密切观察血压、心电图变化,行升主动脉造影评估瓣膜释放后主动脉瓣反流情况,记录院内和出院3个月随访期间主要心脏不良事件的发生情况。 结果: 本研究共纳入13例患者,其中男性7例,年龄为(73.8±8.3)岁。13例患者中三叶式主动脉瓣9例,二叶式主动脉瓣3例,主动脉瓣人工生物瓣置换术后1例。所有患者均在左心室导丝起搏下完成球囊扩张和瓣膜释放,球囊扩张时,以180次/min起搏后,血压均能降至60 mmHg(1 mmHg=0.133 kPa)以下;瓣膜释放过程顺利,位置稳定。升主动脉造影结果显示,瓣膜释放后无反流7例,轻度反流5例,中度反流1例。术中有3例患者因三度房室传导阻滞经股静脉置入临时起搏导线,其中1例住院期间置入永久起搏器,另外2例术后24 h内传导恢复。另有1例患者,术中心电图无明显变化,术后10 d出现三度房室传导阻滞,置入永久起搏器。其余10例患者均在术后24 h开始进行床旁活动、康复训练。住院及出院3个月随访期间无死亡、心肌梗死、卒中等主要心脏不良事件发生。 结论: TAVR中使用左心室导丝起搏是安全、可行的。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Song GY, Liu XM, Teng SY, et al. [Left ventricular guidewire pacing during transcatheter aortic valve replacement]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 34034379. doi:10.3760/cma.j.cn112148-20210401-00294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。